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Abstract 
 
Endometrial cancer remains the most common malignancy of the female genital tract. Lymph 
node metastasis is one of the most important prognostic factors and stratification into pelvic 
lymph node invasion (stage IIIC1) and para-aortic lymph node invasion (stage IIIC2) 
improved the predictive value of the 2009 FIGO classification. 
Radiological examination such as magnetic resonance imaging and positron emission 
tomography–computed tomography do not have good enough sensitivity to avoid 
lymphadenectomy for the assessment of lymph node invasion. Prediction scores are becoming 
more and more valuable to exclude lymph node metastasis in low risk groups and biomarkers 
could help to identify patients with high risk lymph node metastatic probability. 
The therapeutic role of lymph node dissection remains debated. Several endpoints can be 
considered to evaluate the opportunity of lymphadenectomy in endometrial cancer.  
Firstly, we compare survival according to the realization, the extent and the numbers of nodes 
removed during lymphadenectomy. Secondly, we assess the opportunity of lymphadenectomy 
in order to tailor  adjuvant treatment modalities. Thirdly, we analyze the surgical complication 
rate after pelvic  lymphadenectomy. 
 
KEY WORDS: Endometrial cancer; Lymph node metastasis; Prognosis; Staging; 
Lymphadenectomy; Survival; Prediction; Complications.  
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INTRODUCTION 
In Europe, EC (Endometrial Cancer) remains the third cancer diagnosed in 20121. Most cases 
occur in post-menopausal women. Based on histopathology ECs are divided into two 
categories. Type I are typically low-grade adenocarcinomas that are usually estrogen related, 
are diagnosed early and have a favorable prognosis. Type II ECs are not hormone dependent 
and are usually high grade endometrioid adenocarcinomas, papillary serous and clear cell 
carcinomas and carcinosarcomas2.  
Distant organ metastasis is the most important factor in determining patient survival in cancer. 
Metastasis is thought to occur through the blood vascular and lymphatic systems. Cancer cells 
are able to express growth factors and consequently have the capacity to create conduits for 
tumour metastasis. In EC, pelvic LNs (Lymph Nodes) are the most frequent location of 
metastasis. The major lymphatic trunks are the utero-ovarian (infundibulopelvic), parametrial, 
and presacral, which drain into the hypogastric, external iliac, common iliac, presacral, and 
para-aortic nodes3. Although a direct route of lymphatic spread from the corpus uteri to the 
para-aortic through the infundibulopelvic ligament has been suggested from anatomical and 
sentinel LN studies4, direct metastases to the para-aortic LN is uncommon. This reflects how 
lymphatic drainage patterns of the uterus are complex, particularly when compared to those 
observed in mapping studies of cutaneous or breast malignancies. At a larger scale, the 
underlying controversy around the clinical benefit of lymphadenectomy has not been solved. 
Here, we  aim to summarize the main findings related to this commonly performed surgical 
staging procedure. 
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PROGNOSTIC VALUE OF LYMPH NODE METASTASIS 
LN metastasis constitutes one of the most important prognostic factors of EC. Since 1988 this 
information is included in the International Federation of Gynecology and Obstetrics (FIGO) 
classification. In 2009, the FIGO revised the classification of EC. Apart from merging FIGO 
1988 stages IA and IB, LN invasion has been stratified into pelvic LN invasion (stage IIIC1) 
and para-aortic LN invasion (stage IIIC2). The prognostic performances of the 1988 and 2009 
FIGO staging systems have been compared using the concordance indexes. The FIGO staging 
systems were not significantly different5, 6. Others studies however have suggested that the 
2009 FIGO staging system for EC is highly prognostic7, 8, particularly because stages IIIC1 
and IIIC2 have  different prognosis (five year overall survivals are 57% and 49% 
respectively7)  
 
An independent prognostic factor? 
Primary pathological characteristics (myometrial invasion, cervical stromal invasion, 
histological type, lymphovascular space invasion (LVSI) and grade) are associated with the 
occurrence of LN metastasis. Consequently, we cannot exclude that uterine risk factors 
associated with LN metastasis may negatively impact survival independently of LN 
involvement9-11. To answer this question, Barrena Medel et al. compared the prognostic 
significance of uterine risk factor and nodal metastases and determined the independent 
effects on outcome12. Their results suggest that LN metastasis is an independent and the major 
prognostic factor since survival in patients with LN metastasis and without uterine risk factors 
was worse when compared with patients without LN metastasis and with uterine risk factors.  
Another approach in order to determine the prognostic impact of LN metastasis consists in 
building a score to predict survival in EC and in analyzing the impact of lymphadenectomy on 
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the accuracy of this score. Such a score has been developed by Abu Rustum et al.13 and 
validated externally14. This score was designed to predict three year survival probability and 
comprised LN status. More precisely, the number of negative LNs was taken into account in 
this score as well as 1988 FIGO stage, age at diagnosis, final FIGO grade and histologic 
subtype. In this score, LN status was considered for LN metastatic risk assessment since 
FIGO classification was one of the nomogram component and consequently LN positive cases 
were assigned stage IIIC. Base on their preliminary findings showing that patients who had 
more regional LNs examined were likely to be more accurately assigned to the correct FIGO 
stage and because adding positive LNs in the multivariate model did not increase the score’s 
predictive accuracy, the authors decided to include the number of negative LNs into the 
multivariate model. This characteristic remained significantly associated with survival. 
 
 
Lymph Node ratio 
LN ratio is defined as the number of metastatic LNs to the total number of removed LNs. This 
parameter incorporates not only the burden of nodal disease and cancer spread but also the 
extent and quality of surgical staging. Polterauer et al. reported on patients with LN ratios 
10% or less, more than 10–50%, and more than 50% had 5-year overall survival rates of 79%, 
61%, and 36%, respectively (P<.001). In multivariable analysis, only LN ratio was associated 
with both progression-free survival and overall survival. 
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LOCATIONS OF LYMPH NODE METASTASIS 
The incidence of metastases to the pelvic LNs in patients with corpus-confined EC who 
undergo lymphadenectomy varies between 5% and 18%15-18. Para aortic LN metastases are 
observed between 3 to 11% of patients with EC depending on primary tumoral characteristics. 
29 to 67% of patients with pelvic LN metastasis have para aortic involvement15, 19-25. At the 
contrary, only a few percent of patients with negative pelvic LN have para-aortic invasion22. 
Although a direct route of lymphatic spread from the corpus uteri to the para-aortic through 
the infundibulopelvic ligament has been suggested from anatomical studies4, direct metastases 
to the para-aortic LN is uncommon, ranging from 0 to 6% 20, 21, 24, 26-30. 
Mariani et al. have evaluated LN metastatic risk with distinction between the pelvic and para 
aortic areas31. In their prospective study, pelvic and para aortic lymphadenectomies were 
systematically performed in 310 patients with EC (exclusion criteria were: grade 1 or 2 
endometrioid type with myometrial invasion  ≤50% and primary tumor diameter  ≤2 cm).  
Among those patients, 57 patients (22%) had LN invasion and this concerned the pelvic area 
in 19 cases (33%), the para aortic area alone in 9 cases (16%) and in both the pelvic and the 
para aortic areas in 29 cases (51%). Because of the low number of patients with metastatic LN 
in this study (and in patients with EC more generally) the results of this study should be 
interpreted with caution. 
Odagiri et al. recently focused on the precise mapping of LN metastasis sites in EC30. Among 
the 42 patients with positive LN metastasis, 16 cases (38%) in the pelvic area alone, 7 cases 
(16 %) in the para aortic area alone, and 19 cases (45 %) in both the pelvic and para aortic 
areas. One third of positive para aortic LN were above the inferior mesenteric artery (IMA) 
without positive LN below IMA. Metastasis to the deep inguinal nodes was found to be 
extremely rare (0.4 %).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Consequently, for an optimal surgical staging, resection of deep inguinal nodes is not 
recommended, whereas para-aortic lymphadenectomy should be extended up to the level of 
renal veins. Moreover, because metastasis to circumflex iliac nodes distal to external iliac 
nodes (CINDEIN) is extremely rare in patients with positive LN32, 33, those nodes should not 
be systematically removed. 
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PRE OPERATIVE IDENTIFICATION OF LYMPH NODE METASTASIS 
Pelvic and para aortic LN dissection is the recommended method for LN staging in EC. 
However, the probability of LN involvement is low and considering the invasive nature of 
lymphadenectomy, avoidance of unnecessary lymphadenectomy is mandatory. 
 
Magnetic Resonance Imaging (MRI) 
Few studies report the accuracy of MRI for predicting LN metastasis. The major limitation is 
using size criteria alone as thresholds for identifying metastatic LNs based on enlargement 
(usually 10 mm). This size criterion was used in three out of the four studies that showed 
similar diagnostic accuracy for MRI and sentinel-node biopsy in women with EC in the meta-
analysis published by Selman et al.34. This meta-analysis included 18 studies and 693 women. 
A limitation with this meta-analysis is that the included studies did not use diffusion-weighted 
imaging. LN specific magnetic resonance contrast agents which have been developed to 
improve LN staging of pelvic cancers. Sensitivity has been reported between 17 and 66%. 
Specificity appears to be better (73-99%) and since LN metastasis is quite a rare event in EC, 
NPV is excellent (95-98%). 
 
Computed Tomography (CT) scan 
Few studies have evaluated the accuracy of CT scan for predicting LN metastasis in EC. 
Accuracy for LN metastasis ranges from 67 to 88%, with a good NPV (81-94%) but poor 
sensibility and PPV (57% and 31-50% respectively)38, 39.  
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Positron emission tomography/computed tomography (PET/CT) 
PET/CT using fluorine 18 fluorodeoxyglucose (18F-FDG) has been used for staging with 
different results. The results of a recent meta-analysis including 16 studies35, pooled 
diagnostic indices for LN staging were calculated. LN status based on pathology was 
compared to the results of the PET/CT. Unfortunately, the type of metastasis (micro or macro 
metastases) was not reported. We presume that only macrometastasis were considered in the 
studies included in this meta-analysis since the detection and the diagnosis of micrometastasis 
is not performed in routine practice. Results from this meta-analysis are shown in Table 1. 
Only patient basis data are presented.  
 
<insert Table 1 near here> 
 
The pooled sensitivity of 18F-FDG for detection of LN involvement was low, which reduces 
its interest in LN staging of EC. However, the specificity was much better. In other words, 
result of positive 18F-FDG PET in the LN is reliable. Considering pelvic and para-aortic LNs 
separately, accuracy of 18F-FDG PET was higher for para-aortic LN staging when compared 
with the pelvic region. 
PET/CT has been reported to be more useful than PET alone, its CT component yielding 
helpful anatomical and morphological information. However, subgroup analyses regarding 
PET versus PET/CT instruments showed higher sensitivity and lower specificity for PET 
compared with PET/CT studies. These differences were not statistically different between 
PET and PET/CT studies (P = 0.3 for sensitivity and P = 0.8 for specificity)35. 
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Altogether, sensitivity of 18F-FDG PET imaging is not good enough to justify its routine use 
for preoperative LN staging in EC. On the other hand, specificity of 18F-FDG PET imaging is 
adequate. Further studies with large sample size as well as consistently applied pelvic and 
para-aortic lymphadenectomy are definitely needed to be able to draw any more specific 
conclusion. 
Recently, fused PET/MRI images of EC have been compared with 18F-FDG contrast-
enhanced PET/CT and MRI for the prediction of LN metastasis36. Despite patient-based 
sensitivity, specificity and accuracy for detecting pelvic nodal metastasis of 100%, 96% and 
97% for both fused PET/MRI, the low number of patients included (30 cases), makes it non 
recommendable systematic radiological examination for the management of patients with EC. 
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PREDICITNG LYMPH NODE METASTASIS 
Primary tumoral characteristics, demographical characteristics and CA125 level are 
associated with LN metastasis in EC. The strongest association is observed with primary 
tumoral characteristics that include: local extension (myometrial and stroma cervical 
invasion), subtype, grade, diameter and LVSI. Most of those characteristics are assessable pre 
operatively (local extension, subtype, grade, diameter) while LVSI status is not. In particular, 
many studies reported on the accuracy of MRI for the evaluation of the locoregional extension 
of EC. A systematic review that included 11 studies and 548 women reported that on the 
detection of deep myometrial invasion37. The analysis concluded that contrast-enhanced MRI 
has a good diagnostic performance in assessing myometrial invasion of EC and is superior to 
T2-weighted imaging alone. For assessing deep myometrial involvement, its negative 
predictive value appears relative high and negative findings strongly suggest an absence of 
deep myometrial involvement However, both contrast-enhanced and T2-weighted have 
suboptimal positive predictive value.  New imaging sequences, such as diffusion-weighted 
imaging, were only recently introduced and have not been evaluated enough yet. Ultrasound 
has similar performances for predicting myometrial invasion with accuracy between 67 and 
84%38-41. Concerning the prediction of stroma cervical invasion, results of MRI are more 
heterogeneous and less satisfying: accuracy between 46-92%, poor sensitivity and poor 
positive predictive value. Few studies have evaluated the accuracy of CT scan for the 
evaluation of the locoregional extension of EC. Accuracy of CT scan for assessment of the 
outer half of the myometrium ranges between 62 and 87% and very uneven sensibility and 
specificity reported (10-83% and 42-100% respectively)42-44. Concerning cervical stromal 
invasion, performances of CT scan is insufficient, with low sensibility and PPV (20-25% et 9-
14% respectively)36, 38.  
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Scores to predict LN metastasis 
Several authors have proposed different scores in order to predict LN metastasis45-53 (table 2). 
Most of these use primary tumoral extension (myometrial invasion particularly) and a cut-
point was chosen to maximize the negative predictive value and minimize the risk of 
mislabeling patients with nodal involvement.  For all scores, this strategy permits to identify a 
low risk group of patients accounting for approximately half of patients in whom LN 
metastatic probability is extremely low (3% or less). Unfortunately, most of these scores have 
not been validated externally which reduces their generalizability. Similarly, some of those 
scores are based on definitive pathological results and are only applicable once hysterectomy 
has been performed. 
 
<insert Table 2 near here> 
 
Groups risk based on LN metastatic probability 
In 2000, Mariani et al. proposed an algorithm based on readily ascertainable intraoperative 
pathologic indicators that would discriminate a subgroup of early EC that would not require 
lymphadenectomy or adjuvant radiotherapy54. 328 patients with endometrioid EC, grade 1 or 
2 tumor, myometrial invasion ≤50%, and no intraoperative evidence of macroscopic 
extrauterine spread were treated surgically. Pelvic lymphadenectomy was performed in 187 
cases (57%), and nodes were positive in nine cases (5%). Primary tumor diameter and 
lymphatic or vascular invasion significantly affected longevity. No patient with tumor 
diameter ≤2 cm had positive LNs or died of disease. Convery et al. have validated the Mayo 
algorithm in a multi-center retrospective chart review55. Of 110 patients satisfying the Mayo 
algorithm with an adequate lymphadenectomy, 2% were diagnosed with LN metastasis and 
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4% subsequently developed recurrent disease. The Mayo algorithm identified with a 98% 
negative predictive value women who would not benefit from a lymphadenectomy. There was 
no significant difference in recurrence rate between women who underwent 
lymphadenectomy and those who did not when the Mayo algorithm was satisfied. Although a 
small number of patients with advanced stage disease may be missed when applying the 
Mayo criteria, there is no apparent survival benefit to lymphadenectomy for patients 
satisfying this algorithm, and these data support its use at other institutions. 
 
In 2013, the ESMO (European Society for Medical Oncology) separated ECs into three risk 
groups56: 
- Low risk: Stage IA, grade 1 or 2 
- Intermediate risk: Stage IA, grade 3 and Stage IB, grade 1 or 2 
- High risk: Stage IB, grade 3 or Type 2 
 
Because of low risk LN metastatic probability, the ESMO does not recommend 
lymphadenectomy practice in the low risk group. For the intermediate and high risk groups, 
no recommendation is made by the ESMO. 
 
Groups risk based on biomarkers to predict LN metastatic probability 
Other approaches have been conducted to try to estimate LN metastatic risk57. For example, 
double negative hormone receptor status in EC curettage has recently been suggested to 
independently predict LN metastasis57. In Trovik et al. study, 26% of patients with combined 
loss of estrogen-and progesterone receptors expression had LN metastasis. Similarly, stathmin 
immunohistochemical staining seems to be able to identify EC with LN metastases58. The 
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value, as a predictive marker for response to PI3Kinase inhibition and as a tool to stratify 
patients for LN sampling remains to be determined. Unfortunately, the impact of 
lymphadenectomy in terms of survival has not been compared in high risk groups based on 
such biomarkers. Due to the relatively low frequency of LN metastasis and recurrence in low-
risk groups, adequately powered randomized surgical trials have been difficult to conduct. 
Improved tools (such as biomarkers) identifying patients with high risk for LN metastasis 
could reduce the required sample size of a randomized clinical trial assessing survival impact 
of lymphadenectomy. 
A part from those biomarkers, LVSI, which is thought to be the beginnings of lymphatic and 
hematologic metastases has been evaluated in several studies. The interobserver variability in 
the evaluation of lymphatic and blood vessel invasion cannot be neglected because of the 
difficulties in recognizing lymphatic channels and blood vessels using standard hematoxylin 
and eosin staining alone59. This could explain why reported rates of LVSI in EC are 
particularly variable (from 14% to 20% in stage I tumors and between 4% to 37% for all EC 
stages)60. Even in prospective studies, LVSI determination is not systematically performed by 
pathologists. In such cases, two possibilities are raised: the pathologist did not mention the 
presence or absence of LVSI because he did not observe any LVSI or because there was no 
LVSI. Previous studies evaluating LVSI have shown mixed results concerning the impact of 
LVSI on reccurence rate 61-64. Despite those contradictory results, distinction by LVSI status 
has recently been suggested to be more relevant than the distinction between stages IA and IB 
for predicting survival in stage I EC65.  
Concerning the impact of LVSI on LN metastasis, the association has been suggested in 
numerous studies66-68 and LVSI should be considered to be an independent risk factor for LN 
metastasis. Interestingly, in a multicenter study, the risk for LN metastasis is similar when the 
LVSI is negative or is not detailed in the pathological report68. 
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Unfortunately, LVSI status is only available once hysterectomy is performed. Because the 
presence of LVSI increases to a large extent, the decision to perform lymphadenectomy 
because of the presence of LVSI on the hysterectomy specimen, make sense in the perspective 
to remove LN metastasis.  
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SURVIVAL IMPACT OF LYMPHADENECTOMY 
In contrast to the prognostic significance of lymphadenectomy, its therapeutic value remains 
debated. Consequently, there is a high variation in surgical approach worldwide. The 
following approaches are used, including 1/ omitting lymphadenectomy in patients with 
presumed early-stage EC, 2/ performing lymphadenectomy only in patients who are at 
intermediate or high risk for nodal metastases and 3/ performing a complete 
lymphadenectomy in all EC irrespective of grade and depth of myometrial invasion.  
The main reason to perform lymphadenectomy is improvement of survival. Retrospective 
studies have suggested that complete lymphadenectomy may be associated with improved 
survival outcomes, particularly for patients with LN metastases69-72. In their retrospective 
series comparing the outcome of 509 patients with presumed early stage according to the 
number of LNs removed during lymphadenectomy, Cragun et al. have found that patients 
with poorly differentiated cancers having more than 11 pelvic nodes removed had improved 
overall survival and progression-free survival compared with patients having poorly 
differentiated cancers with 11 or fewer nodes removed16.  
Chan et al. based their analysis on the SEER database and consequently evaluated the survival 
impact of lymphadenectomy on the largest sample of patients with presumed early stage EC73. 
In this study, lymphadenectomy did not improve survival in patients with low risk. At the 
contrary, in other stages (Stage IB, Grade 3; Stage IC and II-IV), an extensive LN resection 
was associated with improved 5-year disease-specific survivals. 
Two randomized clinical trials showed that lymphadenectomy did not show an overall or 
recurrence free survival benefit in the early stages of disease. These trials have been criticized 
for the following reasons: a limited effort with respect to the extent of dissection and LN 
evaluation, too many low-risk patients, and no direct decision on adjuvant therapy based on 
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lymphadenectomy result. In particular, ASTEC study has suggested that that there is no 
benefit from either pelvic lymphadenectomy or postoperative pelvic radiation17.  Concerning 
the other randomized study, the Italian trial also showed no improvement in survival for 
women after pelvic lymphadenectomy, although there was a marginal decrease in the use of 
postoperative adjuvant radiation therapy after a staging procedure18. 
 
Because pelvic lymphadenectomy was not proven to have any therapeutic benefit for EC, the 
SEPAL study » (Survival Effect of Para-Aortic Lymphadenectomy in endometrial cancer) 
was conducted to establish whether complete, systematic lymphadenectomy, including the 
para-aortic LNs, should be part of surgical therapy for patients at intermediate and high risk of 
recurrence74. In this retrospective study, both overall and cancer related survival were 
significantly longer in the pelvic and para-aortic lymphadenectomy group than in the pelvic 
lymphadenectomy group. This association was also recorded in patients at intermediate or 
high risk, but overall survival was not related to lymphadenectomy type in low-risk patients. 
Multivariate analysis of prognostic factors showed that in patients with intermediate or high 
risk of recurrence, pelvic and para-aortic lymphadenectomy reduced the risk of death 
compared with pelvic lymphadenectomy. Analysis of patients with intermediate or high risk 
who were treated with adjuvant radiotherapy or chemotherapy showed that patient survival 
improved with pelvic and para-aortic lymphadenectomy and with adjuvant chemotherapy 
independently of one another. In this study, all EC subtypes and stages were included both 
most tumors were presumed to be limited to the corpus uteri. Importantly, tumoral 
characteristics were similar between the two groups. However, the main concern about the 
SEPAL study is that concerning adjuvant therapy, the two groups were not comparable. In 
patients who underwent both pelvic and para-aortic lymphadenectomy, 77% received 
chemotherapy whereas this was given in 45% of patients who underwent pelvic 
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lymphadenectomy alone. Finally, if this study suggests the benefit of both pelvic and para-
aortic lymphadenectomy is beneficial in comparison with patients who will undergo pelvic 
lymphadenectomy alone, it does not imply that extensive lymphadenectomy improves 
survival in comparison with no lymphadenectomy since abstention for lymphadenectomy was 
not reported in the SEPAL study. 
Taken together, the benefit of lymphadenectomy is less important than we once believed. 
Nevertheless, lymphadenectomy may help to select patients who need adjuvant therapy (see 
below). 
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COMPLICATIONS OF LYMPHADENECTOMY 
If lymphadenectomy was not associated with increased surgical morbidity, it is probable that 
its practice would not be such a matter of debate. Unfortunately, it is difficult to assess 
complication rate associated to lymphadenectomy for numerous reasons. 
First, in most studies complications rate is only a secondary objective33, 67, 68. Second, in many 
it is often difficult to distinguish complications related to the hysterectomy and those related 
to the lymphadenectomy. Third, the administration of adjuvant radiotherapy should be taken 
into account for the interpretation of lymphadenectomy related complication. Similarly, 
because patients EC often have comorbidities such as diabetes, high blood pressure or 
obesity, analysis for the occurrence of lymphadenectomy complication should be interpreted 
with caution.  
Because of all those limitations, reported complication rates after lymphadenectomy are 
particularly variable from one study to another75, 76. In patients without adjuvant radiotherapy, 
reported rates vary between 6 to 25 %75, 77-79. Contradictory results have been published 
concerning the impact of lymphadenectomy on overall complication rate17, 18, 79. However, the 
two randomized studies concerning the impact of lymphadenectomy both reported a higher 
rate of complications in the lymphadenectomy groups17, 18. Moreover, it is well admitted that 
lymphadenectomy increases intra operative complication rate, with increased vascular injury 
rate and requires blood transfusion more frequently31. In the ASTEC study, the risk of 
developing short-term major surgical complications was low in both groups but more women 
in the lymphadenectomy group developed specific complications of: ileus, deep-vein 
thrombosis, lymphocyst and major wound dehiscence. 
Concerning the extent of lymphadenectomy, contradictory results have been published about 
the impact of para-aortic lymphadenectomy on the surgical morbidity or radiation-related 
complications in comparison with patients undergoing pelvic lymphadenectomy only. Some 
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published that para-aortic lymphadenectomy does not contribute to increased complications80 
while others  reported that para-aortic lymphadenectomy increases both blood loss and time 
of surgery19, 80. At the contrary, the laparoscopic route has been related to a lower blood loss 
and lower rate of surgical complications81.  
Lymphedema remains the main late complication associated with lymphadenectomy. To 
compare the quality of life (QoL) of women with lower limb lymphedema (LLL), to women 
with lower limb swelling (LLS), and to women without LLL or LLS following treatment for 
EC, Rowlands et al. sent a follow-up questionnaire 3-5 years after EC diagnosis. The 639 
women who responded were categorized as: Women with LLL (n=68), women with LLS 
(n=177) and women without LLL or LLS (n=394). Although LLL was associated with 
reductions in physical QoL, LLS was related to reductions in both physical and mental QoL.  
The risk for lymphedema is correlated to the number of LN removed82. It has recently been 
reported that resection of more than 31 LNs and removal of CINDEIN were significantly 
related to the occurrence of postoperative lower-extremity lymphedema in EC32. Abu-Rustum 
et al. suggested that removal of CINDEIN is likely to be a factor contributing to the risk of 
postoperative lower extremity lymphedema82. Hareyama et al. recently reported that 
preservation of CINDEIN could reduce or prevent the incidence of lower extremity 
lymphedema after systematic lymphadenectomy for patients with gynecologic malignancies33.  
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DECISION FOR ADJUVANT TREATMENT BASED ON LYMPHADENECTOMY  
Some authors advocate a therapeutic benefit of lymphadenectomy in early EC to tailor 
adjuvant therapy in high risk patients83-85. However, as previously detailed, LN metastasis is 
usually found in patients with uterine risk factors that could justify adjuvant treatment in EC 
irrespectively to the LN status. Indeed, patients with high-risk early stage EC treated with 
adjuvant chemoradiotherapy have a lower rate of recurrence compared to those not receiving 
such therapy86. 
On the one hand, it seems logical to avoid a treatment characterised by morbidity and costs 
without survival benefit (ie, radiotherapy) by choosing another procedure (ie, 
lymphadenectomy) to select patients who will benefit from radiotherapy on a survival point of 
view. On the other hand, we believe important to remind that none of the five randomized 
studies evaluating adjuvant radiotherapy in stage I EC has shown improved survival in 
patients treated with adjuvant radiotherapy87-91.  
The benefit of chemotherapy in early stage EC has been poorly investigated92, 93. In Randall et 
al. trial comparing whole-abdominal irradiation and doxorubicin-cisplatin chemotherapy in 
women with stage III or IV EC having a maximum of 2 cm of postoperative residual disease, 
chemotherapy significantly improved survival compared with whole-abdominal irradiation94. 
Since approximately half of patients where stage III because of metastatic LN (FIGO 1988 
Stage IIIC), these results constitute a strong argument for adequate systematic surgical staging 
(including LN assessment) and justify to deliver chemotherapy in patients with metastatic 
LN20, 93, 95.   This study is pivotal since it showed for the first time that EC is a chemosensitive 
disease. 
In Hogberg et al. study randomizing patients with stage I-III high risk EC receiving adjuvant 
radiotherapy with or without sequential chemotherapy, in patients not undergoing 
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lymphadenectomy, chemotherapy resulted in a gain of survival to the same extent than those 
who underwent lymphadenectomy96. Unfortunately, because only 26% of patients underwent 
pelvic lymphadenectomy (i.e. LN assessment), it was not possible to compare the impact of 
chemotherapy according to the LN status and we can not exclude that chemotherapy is 
beneficial in patients with positives LN only. It is possible that LN negative patients do not 
benefit from chemotherapy and in such patients we could safely avoid chemotherapy 
administration. The ongoing EORCT 55012 trial  aims to answer this question by comparing 
survival in patients with stage I grade 3 endometrioid EC, stage I and II type 2 EC  or stage II 
endometrioid EC and without metastatic LN after randomization for adjuvant chemotherapy. 
If survival in patients receiving adjuvant chemotherapy is better in patients receiving 
chemotherapy, LN assessment should not remain a standard procedure for LN negative 
intermediate and high risk EC since benefit of adjuvant chemotherapy will be proven 
irrespective for LN status. At the contrary, if no benefit is observed in patients receiving 
adjuvant chemotherapy, LN assessment will permit to avoid unnecessary chemotherapy side 
effects in LN negative patients. 
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SENTINEL LYMPH NODE (SLN) BIOPSY 
The SLN is defined as the first LN in the lymphatic system that drains a tumor site. If the SN 
is not metastatic, all other LNs should also be disease-free. The SLN procedure has been 
suggested to reliably predict the metastatic status of the regional LNs in early stage EC. Two 
main outcomes should be assessed when evaluating the interest of the SLN biopsy procedure. 
First, could be it a trade-off between systematic lymphadenectomy and no dissection at all? 
From the largest study evaluating the value of SLN biopsy97 in EC, we can conclude that this 
strategy is not appropriate in high risk disease. In this trial, all three false-negative patients 
had type 2 EC. Concerning low and intermediate risk, in a recent meta-analysis, 35 studies 
with enough information for false negative rate evaluation and 51 studies (including the sub-
groups of individual studies) for detection rate evaluation (2,071 patients overall) were 
included. Pooled detection rate was 78% and pooled sensitivity was 89%98. Cervical injection, 
as well as using both blue dye and radiotracer, resulted in higher detection rate and sensitivity. 
Using both blue dye and radiotracer and cervical injection of the mapping material could 
improve the sensitivity and detection rate of this technique. Larger studies are still needed to 
evaluate the false negative rate and the factors influencing the sensitivity before considering 
this method safe.   
Second, the SLN biopsy procedure permits to identify “low-volume LN metastases”99 because 
pathologic ultrastaging is the only method allowing detection of such LN disease. The 
frequency of such “low-volume, ultrastage-detected LN metastases” has been reported to be 
around 5% and interestingly, in such patients, the rate of micrometastases and isolated tumor 
cells does not seem to be correlated with myometrial invasion99 and primary tumoral 
aggressiveness100. However, the oncologic significance of “low volume LN metastases” has 
not been reported yet. 
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Practice points 
• Lymph node metastasis constitutes a major independent prognostic factors of 
endometrial cancer 
• Stages IIIC1(pelvic lymph node invasion) and IIIC2 (para-aortic lymph node invasion) 
have very different prognosis 
• A few percent of patients with negative pelvic lymph node have para-aortic invasion 
• For optimal LN metastatic resection in endometrial cancer, resection of deep inguinal 
nodes is not recommended, whereas para-aortic lymphadenectomy should be extended 
up to the level of renal veins. 
• MRI and successful sentinel node biopsy are the most preoperative accurate tests for 
identifying LN metastasis. 
• Result of positive 18F-FDG PET in the LN is reliable for the diagnosis of metastasis. 
• Various scores mainly based on primary tumoral characteristics are available to 
predict LN metastasis. Most of them have not been externally validated but can permit 
to avoid lymphadenectomy in half of patients. 
• LVSI should be considered to be an independent risk factor for LN metastasis. 
• In low risk group patients, lymphadenectomy has no impact on survival.  
• In intermediate and high risk group patients, the therapeutic impact of 
lymphadenectomy is not proven. But, the procedure can identify patients that may 
benefit from adjuvant chemotherapy 
• Lymphadenectomy is associated with a higher rate of complications. The risk for 
lymphedema is correlated to the number of LN removed. 
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Research agenda 
• Evaluation of new imaging techniques to identify metastatic LN in patients with EC 
(such as fused PET/MRI) 
• Comparison of the various scores to predict metastatic LN  
• Identification of biomarkers able to predict metastatic LN pre operatively 
• Identification of a subgroup of patients who will benefit of lymphadenectomy in terms 
of survival 
• Technique of sentinel lymph node procedure 
• Identification of patients who will benefit from sentinel lymph node biopsy 
• Cost effectiveness analysis for lymphadenectomy practice in EC 
• The value of adjuvant chemotherapy in node negative disease 
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Table 1. Diagnostic performance of 18-F-FDG PET imaging for Lymph node staging of 
endometrial cancer. 
 Sensitivity,% Specificity,% LR+ LR- DOR 
LN overall 72 (64-80) 93 (91-95) 8.4 (5.9-11.8) 0.4 (0.2-0.5) 27.7 (15.8-48.6) 
Pelvic LN 61 (48-73) 97 (95-99) 15.4 (8.6-27.5) 0.4 (0.2-0.9) 42.0 (18.8-93.6) 
PA LN 87 (66-97) 99 (97-100) 46.6 (18.4-117.9) 0.1 (0.05-0.4) 309 (70.6-1352) 
LR+: Positive likelihood ratio 
LR-: Negative likelihood ratio 
DOR: Diagnostic odds ratio 
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Table 2. Available scores to predict lymph node metastatic in patients with endometrial cancer  
Score Components Evaluated Externaly 
validated Low risk 
Kang et al. 201250 CA125, MRI locoregional extension (myometrial invasion, LN enlargement, and extension beyond uterine corpus) Pre operatively Yes 
43% 
1.4% 
Lee et al. 201047 CA125, grade, MRI locoregional extension (disease extent 
and myometrial invasion) Pre operatively No 
57% 
0% 
Kamura et al. 
199946 
Pathological local extension 
(tumor diameter and myometrial invasion) Post operatively No Not reported 
Todo et al. 200748, 
51
 
CA125, tumor grade/histology, MRI local extension (volume 
index) Pre operatively Yes 
54% 
3% 
Luomaranta et al. 
201349 
Biochemical factors (leukocytosis, thrombocytosis and 
CA125 level) and preoperative tumor characteristics Pre operatively No Not reported 
Bendifallah et al. 
201245, 52 
Pathological hysterectomy characteristics (subtype; grade and 
myometrial and cervical invasion), age and race 
Pre operatively and 
Post operatively Yes 
54% 
0% 
Milam et al. 201253 Uterine pathology characteristics (myometrial invasion, tumor 
size, and differentiation) Post operatively No 
40% 
0.8% 
